Humana Inc. (NYSE:HUM) Shares Sold by Regent Investment Management LLC

Regent Investment Management LLC lowered its holdings in Humana Inc. (NYSE:HUMGet Rating) by 3.0% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,285 shares of the insurance provider’s stock after selling 100 shares during the period. Regent Investment Management LLC’s holdings in Humana were worth $1,538,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in HUM. Quadrant Capital Group LLC grew its holdings in Humana by 3.0% during the 1st quarter. Quadrant Capital Group LLC now owns 845 shares of the insurance provider’s stock worth $368,000 after acquiring an additional 25 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its holdings in Humana by 3.5% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 730 shares of the insurance provider’s stock worth $318,000 after acquiring an additional 25 shares in the last quarter. CVA Family Office LLC grew its holdings in Humana by 12.8% during the 2nd quarter. CVA Family Office LLC now owns 220 shares of the insurance provider’s stock worth $103,000 after acquiring an additional 25 shares in the last quarter. Allworth Financial LP grew its holdings in Humana by 10.9% during the 2nd quarter. Allworth Financial LP now owns 255 shares of the insurance provider’s stock worth $119,000 after acquiring an additional 25 shares in the last quarter. Finally, AdvisorNet Financial Inc grew its holdings in Humana by 18.8% during the 2nd quarter. AdvisorNet Financial Inc now owns 164 shares of the insurance provider’s stock worth $77,000 after acquiring an additional 26 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

Humana Stock Performance

Humana stock traded down $13.27 during trading hours on Friday, reaching $480.64. 23,065 shares of the stock were exchanged, compared to its average volume of 868,719. The stock has a market cap of $60.82 billion, a P/E ratio of 19.62, a P/E/G ratio of 1.43 and a beta of 0.77. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.53 and a current ratio of 1.53. Humana Inc. has a 52-week low of $351.20 and a 52-week high of $514.98. The firm’s 50 day moving average is $487.67 and its 200 day moving average is $460.98.

Humana (NYSE:HUMGet Rating) last announced its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 EPS for the quarter, topping analysts’ consensus estimates of $7.67 by $1.00. The company had revenue of $23.66 billion during the quarter, compared to the consensus estimate of $23.44 billion. Humana had a net margin of 3.52% and a return on equity of 18.42%. Humana’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.89 EPS. Analysts predict that Humana Inc. will post 24.99 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 30th will be given a dividend of $0.7875 per share. The ex-dividend date is Thursday, September 29th. This represents a $3.15 dividend on an annualized basis and a yield of 0.66%. Humana’s payout ratio is currently 12.86%.

Insiders Place Their Bets

In other news, insider Joseph C. Ventura sold 1,226 shares of the company’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $506.78, for a total transaction of $621,312.28. Following the transaction, the insider now directly owns 3,930 shares of the company’s stock, valued at approximately $1,991,645.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.39% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Truist Financial boosted their price target on shares of Humana from $550.00 to $570.00 and gave the stock a “hold” rating in a report on Friday, September 16th. Sanford C. Bernstein assumed coverage on shares of Humana in a research report on Thursday, May 26th. They set a “market perform” rating and a $506.00 price objective for the company. SVB Leerink boosted their price objective on shares of Humana from $535.00 to $540.00 and gave the stock an “outperform” rating in a research report on Thursday, July 28th. Loop Capital assumed coverage on shares of Humana in a research report on Thursday, June 16th. They set a “buy” rating and a $510.00 price objective for the company. Finally, Royal Bank of Canada boosted their price objective on shares of Humana from $541.00 to $544.00 and gave the stock an “outperform” rating in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $519.28.

Humana Company Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMGet Rating).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.